Golgi protein 73 versus alpha-fetoprotein as a biomarker for hepatocellular carcinoma: A diagnostic meta- analysis

BMC Cancer

Volumn 12, Issue , 2012, Pages

  Zhou, Ying ^a   Yin, Xin ^a   Ying, Jun ^a   Zhang, BoHeng ^a  

^a FUDAN UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA FETOPROTEIN; GOLGI PROTEIN 73; TUMOR MARKER; UNCLASSIFIED DRUG; GOLM1 PROTEIN, HUMAN; MEMBRANE PROTEIN;

AREA UNDER THE CURVE; ARTICLE; CANCER DIAGNOSIS; CELL HETEROGENEITY; CONFIDENCE INTERVAL; CONTROLLED STUDY; DIAGNOSTIC ACCURACY; DIAGNOSTIC TEST ACCURACY STUDY; DNA EXTRACTION; HUMAN; INTERMETHOD COMPARISON; LIVER CELL CARCINOMA; META ANALYSIS; PREVALENCE; QUALITY CONTROL; RECEIVER OPERATING CHARACTERISTIC; SENSITIVITY AND SPECIFICITY; SYSTEMATIC REVIEW; BLOOD; LIVER TUMOR; REVIEW;

ALPHA-FETOPROTEINS; CARCINOMA, HEPATOCELLULAR; HUMANS; LIVER NEOPLASMS; MEMBRANE PROTEINS; SENSITIVITY AND SPECIFICITY; TUMOR MARKERS, BIOLOGICAL;

EID: 84855783777     PISSN: None     EISSN: 14712407     Source Type: Journal    
DOI: 10.1186/1471-2407-12-17     Document Type: Article

References (40)

1. Ferlay J, Shin HR, Bray F, Forman D, Mathers C, Parkin DM. GLOBOCAN 2008 v1.2, Cancer Incidence and Mortality Worldwide: IARC CancerBase No. 10 [Internet]. Lyon, France: International Agency for Research on Cancer. 2010, , http://globocan.iarc.fr
2. Fattovich G, Stroffolini T, Zagni I, Donato F. Hepatocellular carcinoma in cirrhosis: incidence and risk factors. Gastroenterology 2004, 127(Suppl1):35-50.
3. Oka H, Tamori A, Kuroki T, Kobayashi K, Yamamoto S. Prospective study of alpha-fetoprotein in cirrhotic patients monitored for development of hepatocellular carcinoma. Hepatology 1994, 19:61-67. 10.1002/hep.1840190111, 7506227.
4. Pateron D, Ganne N, Trinchet JC, Aurousseau MH, Mal F, Meicler C, Coderc E, Reboullet P, Beaugrand M. Prospective study of screening for hepatocellular carcinoma in Caucasian patients with cirrhosis. J Hepatol 1994, 20:65-71. 10.1016/S0168-8278(05)80468-4, 7515408.
5. Zoli M, Magalotti D, Bianchi G, Gueli C, Marchesini G, Pisi E. Efficacy of a surveillance program for early detection of hepatocellular carcinoma. Cancer 1996, 78:977-983. 10.1002/(SICI)1097-0142(19960901)78:5<977::AID-CNCR6>3.0.CO;2-9, 8780534.
6. Saffroy R, Pham P, Reffas M, Takka M, Lemoine A, Debuire B. New perspectives and strategy research biomarkers for hepatocellular carcinoma. Clin Chem Lab Med 2007, 45:1169-1179. 10.1515/CCLM.2007.262, 17635075.
7. Block TM, Comunale MA, Lowman M, Steel LF, Romano PR, Fimmel C, Tennant BC, London WT, Evans AA, Blumberg BS, et al. Use of targeted glycoproteomics to identify serum glycoproteins that correlate with liver cancer in woodchucks and humans. Proc Natl Acad Sci 2005, 102:779-784. 10.1073/pnas.0408928102, 545516, 15642945.
8. Whiting P, Rutjes AWS, Reitsma JB, Bossuyt PM, Kleijnen J. The development of QUADAS: a tool for the quality assessment of studies of diagnostic accuracy included in systematic reviews. BMC Medical Res Methodology 2003, 3:25.
9. Bruix J, Sherman M, Llovet JM, Beaugrand M, Lencioni R, Burroughs AK, Christensen E, Pagliaro L, Colombo M, Rodes J, . EASL Panel of Experts on HCC Clinical management of hepatocellular carcinoma, conclusions of the Barcelona-2000 EASL conference. J Hepatol 2001, 35:421-430. 10.1016/S0168-8278(01)00130-1, 11592607, EASL Panel of Experts on HCC.
10. Li LJ, Li XF, Wang GX. Significance of Golgi protein 73, alpha-fetoprotein and vascular endothelial growth factor expression in diagnosis of primary hepatic cancer. World Chinese J Digestology 2009, 17:3056-3060.
11. Riener MO, Stenner F, Liewen H, Hellerbrand C, Bahra M, Kristiansen G. Alpha-fetoprotein and serum golgi phosphoprotein 2 are equally discriminative in detecting early hepatocellular carcinomas. Hepatology 2009, 50:326.
12. Yamamoto K, Imamura H, Matsuyama Y, Ikeda H, Norman GL, Shums Z, Aoki T, Hasegawa K, Beck Y, Sugawawa Y, et al. A prospective study of measurements of four tumor markers in patients with hepatocellular carcinoma (HCC). Hepatology 2009, 50(SUPPL):1096A.
13. Stenner F, Heike Liewen HL, Panagiotis Samaras PS, Holger Moch HM, Alexander Knuth AK, Marc-Oliver Riener MOR, Kristiansen G, Renner C, Bahra M, Hellerbrand C. The emerging role of the novel serum marker GOLPH2 in detecting and monitoring of hepatocellular carcinoma. European J Cancer 2009, 7:404-405.
14. Yamamoto K, Imamura H, Matsuyama Y, Kume Y, Ikeda H, Norman GL, Shums Z, Aoki T, Hasegawa K, Beck Y, et al. AFP, AFP-L3, DCP, and GP73 as markers for monitoring treatment response and recurrence and as surrogate markers of clinicopathological variables of HCC. J Gastroenterol 2010, 45:1272-1282. 10.1007/s00535-010-0278-5, 20625772.
15. Riener MO, Stenner F, Liewen H, Hellerbrand C, Bahra M, Kristiansen G. Golgi phosphoprotein 2 (GOLPH2) expression in liver tumors and its value as a serum marker in hepatocellular carcinomas. Hepatology 2009, 49:1602-1609. 10.1002/hep.22843, 19291786.
16. Li X, Wu K, Fan D. Serum Golgi phosphoprotein 2 level: A better marker than alpha-fetoprotein for diagnosing early hepatocellular carcinoma. Hepatology 2009, 50:325. 10.1002/hep.23028, 19492428.
17. Tan LY, Chen J, Wang H, Ye HQ, Li Q, Gu JA, Han LQ. Correlation between serum Golph2 protein and hepatocellular carcinoma. Chinese J Hepatol 2009, 17:288-291.
18. Gu Y, Chen W, Zhao Y, Chen L, Peng T. Quantitative analysis of elevated serum Golgi protein-73 expression in patients with liver diseases. Ann Clin Biochem 2009, 46:38-43. 10.1258/acb.2008.008088, 19008260.
19. Mao YL, Yang HY, Xu HF, Sang XT, Lu X, Yang ZY, Zhang JC, Zhong SX, Huang JF, Zhang HB. Significance of Golgi glycoprotein 73, a new tumor marker in diagnosis of hepatocellular carcinoma: a primary study. Zhonghua Yi Xue Za Zhi 2008, 88:948-951.
20. Chen W, Yang HY, Mao YL, Zhang JC, Xu HF, Jiang GY, Jin YL, Chen XX, Lu X, Sang XT, et al. Value of Golgi protein 73 monoclonal antibody in diagnosis of hepatocellular carcinoma. Acta Academiae Medicinae Sinicae 2011, 33:39-44.
21. Shi Y, Chen J, Li L, Sun Z, Zen L, Xu S, Zhang Y, Zhang L. A study of diagnostic value of Golgi protein GP73 and its genetic assay in primary hepatic carcinoma. Technol Cancer Res Treat 2011, 10:287-294.
22. Hu JS, Wu DW, Liang S, Miao XY. GP73, a resident Golgi glycoprotein, is sensibility and specificity for hepatocellular carcinoma of diagnosis in a hepatitis B-endemic Asian population. Med Oncol 2010, 27:339-345. 10.1007/s12032-009-9215-y, 19399652.
23. Morota K, Morota K, Nakagawa M, Sekiya R, Hemken PM, Sokoll LJ, Elliott D, Chan DW, Dowell BL. A comparative evaluation of Golgi protein-73, fucosylated hemopexin, (alpha)-fetoprotein, and PIVKA-II in the serum of patients with chronic hepatitis, cirrhosis, and hepatocellular carcinoma. Clin Chem Lab Med 2011, 49:711-718. 10.1515/CCLM.2011.097, 21231906.
24. Ozkan H, Erdal H, Tutkak H, Karaeren Z, Yakut M, Yuksel O, Koklu S. Diagnostic and prognostic validity of Golgi protein 73 in hepatocellular carcinoma. Digestion 2010, 83:83-88.
25. Mao Y, Yang H, Xu H, Lu X, Sang X, Du S, Zhao H, Chen W, Xu Y, Chi T, et al. Golgi protein 73 (GOLPH2) is a valuable serum marker for hepatocellular carcinoma. Gut 2010, 59:1687-1693. 10.1136/gut.2010.214916, 20876776.
26. Marrero JA, Romano PR, Nikolaeva O, Steel L, Mehta A, Fimmel CJ, Comunale MA, D'Amelio A, Lok AS, Block TM. GP73, a resident Golgi glycoprotein, is a novel serum marker for hepatocellular carcinoma. J Hepatol 2005, 43:1007-1012. 10.1016/j.jhep.2005.05.028, 16137783.
27. Tian L, Wang Y, Xu D, Gui J, Jia X, Tong H, Wen X, Dong Z, Tian Y. Serological AFP/Golgi protein 73 could be a new diagnostic parameter of hepatic diseases. Int J Cancer 2011, 7:6.
28. Wang M, Long RE, Comunale MA, Junaidi O, Marrero J, Di Bisceglie AM, Block TM, Mehta AS. Novel fucosylated biomarkers for the early detection of hepatocellular carcinoma. Cancer Epidemiol Biomarkers and Prev 2009, 18:1914-1921.
29. Whiting P, Harbord R, Kleijnen J. No role for quality scores in systematic reviews of diagnostic accuracy studies. BMC Med Res Methodol 2005, 5:19. 10.1186/1471-2288-5-19, 1184082, 15918898.
30. Deeks JJ. Systematic reviews in health care: systematic reviews of evaluations of diagnostic and screening tests. BMJ 2001, 323:157-62. 1120791, 11463691.
31. Walter SD. Properties of the summary receiver operating characteristic (SROC) curve for diagnostic test data. Stat Med 2002, 21:1237-56. 10.1002/sim.1099, 12111876.
32. Kladney RD, Bulla GA, Guo L, Mason AL, Tollefson AE, Simon DJ, Koutoubi Z, Fimmel CJ. GP73, a novel Golgi-localized protein upregulated by viral infection. Gene 2000, 249:53-65. 10.1016/S0378-1119(00)00136-0, 10831838.
33. Sangiovanni A, Romeo R, Prati GM, Manini MA, Lavarone M, Ronchi G, Colombo M. Serum expression of lectin reactive α-fetoprotein, des-γ-carboxy prothrombin, Golgi protein-73 antigen and antibody, for the diagnosis of hepatocellular carcinoma [abstract]. Hepatology 2007, 46(suppl1):406A.
34. Comunale MA, Mattu TS, Lowman MA, Evans AA, London WT, Semmes OJ, Ward M, Drake R, Romano PR, Steel LF, Block TM, Mehta A. Comparative proteomic analysis of de-N-glycosylated serum from hepatitis B carriers reveals polypeptides that correlate with disease status. Proteomics 2004, 4:826-838. 10.1002/pmic.200300625, 14997503.
35. Phases of Biomarker Development for Early Detection of Cancer. J National Cancer Inst 2001, 93:1054-61.
36. Wright LM, Kreikemeier JT, Fimmel CJ. A concise review of serum markers for hepatocellular cancer. Cancer Detection and Prev 2007, 31:35-44.
37. Petitti DB. Approaches to heterogeneity in meta-analysis. Stat Med 2001, 20:3625-33. 10.1002/sim.1091, 11746342.
38. Whiting P, Rutjes AW, Reitsma JB, Glas AS, Bossuyt PMM, Kleijnen J. Sources of variation and bias in studies of diagnostic accuracy: a systematic review. Ann Intern Med 2004, 140:189-202.
39. Higgins J, Thompson S, Deeks J, Altman D. Statistical heterogeneity in systematic reviews of clinical trials: a critical appraisal of guidelines and practice. J Health Services Res and Policy 2002, 7:51-61.
40. Song F, Khan KS, Dinnes J, Sutton AJ. Asymmetric funnel plots and publication bias in meta-analyses of diagnostic accuracy. Int J Epidemiol 2002, 31:88-95. 10.1093/ije/31.1.88, 11914301.